Form 4: NVNO Director Sells Shares Under 10b5-1 Plan

enVVeno Medical Corp Director Francis Duhay sold 4,900 shares of common stock for a weighted-average price of $0.83 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Francis Duhay, a Director of enVVeno Medical Corp (NVNO), reported a sale of common stock.
• The transaction involved 4,900 shares of common stock.
• The shares were sold at a weighted-average price of $0.83 per share, with individual trades ranging from $0.8205 to $0.84.
• The sale was executed on September 15, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Duhay in June 2025.
• Following this transaction, Mr. Duhay directly beneficially owns 97,444 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a pre-scheduled sale under a Rule 10b5-1 plan, indicating it was not based on new material non-public information. While an insider sale can sometimes be viewed negatively, the pre-planned nature mitigates significant negative sentiment.

Positives

• NA

Negatives

• Director Francis Duhay sold 4,900 shares of common stock, which could be perceived negatively by some investors, despite being part of a pre-arranged 10b5-1 trading plan.

Risks

• NA

Future Outlook

NA

Industry Context

NA

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders may interpret the director's sale of shares as a signal, though the pre-arranged 10b5-1 plan suggests the decision was made without reliance on new material non-public information.

Next Steps

• NA

Key Dates

Keywords

enVVeno Medical Corp, NVNO, Form 4, Insider Sale, Francis Duhay, Director, 10b5-1 Plan, Stock Transaction